Lund Arthritis Research Group (LARG)
1 – 50 of 89
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Belonging, happiness, freedom and empowerment-a qualitative study of patients' understanding of health in early rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy : results from the ICEBIO registry
2024) In Scandinavian Journal of Rheumatology(
- Contribution to journal › Article
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
2024) In ACR Open Rheumatology(
- Contribution to journal › Article
-
Mark
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study
(
- Contribution to journal › Article
-
Mark
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries
(
- Contribution to journal › Article
-
Mark
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
(
- Contribution to journal › Article
-
Mark
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis : Results From the European Spondyloarthritis Research Collaboration Network
(
- Contribution to journal › Article
-
Mark
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)
(
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
(
- Contribution to journal › Article
-
Mark
Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients
(
- Contribution to journal › Article
-
Mark
Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis : what is the role of inflammation control?
(
- Contribution to journal › Article
- 2023
-
Mark
The effect of a tight control regime with monthly follow-up on remission rates and reported pain in early rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network
(
- Contribution to journal › Article
-
Mark
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: Data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
(
- Contribution to journal › Article
-
Mark
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
(
- Contribution to journal › Article
-
Mark
How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
-
Mark
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
(
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
(
- Contribution to journal › Scientific review
-
Mark
Healthcare professionals' perceptions of working on lifestyle management for patients with early rheumatoid arthritis - a qualitative study
2023) In International Journal of Qualitative Studies on Health and Well-being 18(1). p.2241225-2241225(
- Contribution to journal › Article
-
Mark
Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis : an observational nationwide study
(
- Contribution to journal › Article
-
Mark
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
(
- Contribution to journal › Article
-
Mark
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice : Results from the ARTIS programme
(
- Contribution to journal › Article
-
Mark
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017
(
- Contribution to journal › Article
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
(
- Contribution to journal › Article
-
Mark
Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout
(
- Contribution to journal › Article
-
Mark
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
(
- Contribution to journal › Article
-
Mark
Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register
(
- Contribution to journal › Article
-
Mark
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis : A Decision Tree Analysis by Indication
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA) : A Retrospective Observational Study
(
- Contribution to journal › Article
-
Mark
Outpatient Use of Antimicrobials in Patients With Rheumatoid Arthritis Before and After Treatment With Tumor Necrosis Factor Inhibitors : A Nationwide Retrospective Cohort Study
(
- Contribution to journal › Article
-
Mark
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration
(
- Contribution to journal › Article
-
Mark
Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients
(
- Contribution to journal › Article
-
Mark
Comparison of chronic widespread pain prevalence with different criteria in two cohorts of rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis : Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
(
- Contribution to journal › Article
-
Mark
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
(
- Contribution to journal › Article
-
Mark
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
(
- Contribution to journal › Article
- 2021
-
Mark
Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis : results from the randomised controlled SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics : A Nordic population-based cohort study
(
- Contribution to journal › Article
-
Mark
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine
(
- Contribution to journal › Article
-
Mark
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : A nationwide Swedish cohort study
(
- Contribution to journal › Article
-
Mark
Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds
(
- Contribution to journal › Article
-
Mark
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis
(
- Contribution to journal › Article
-
Mark
Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study
(
- Contribution to journal › Article
-
Mark
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : From infection severity to impact on care provision
(
- Contribution to journal › Article
-
Mark
Patients' Perceptions of Person-Centered Care in Early Rheumatoid Arthritis: A Qualitative Study
(
- Contribution to journal › Article